NIH R01 · 2025
A New Paradigm for Iron Replacement Therapy
Project Summary/ Abstract Anemia impacts ~25% of the world’s population and contributes to adverse outcomes. Several forms of anemia, including anemia of inflammation (AI) and iron-refractory iron deficiency anemia (IRIDA) are caused in part by pathologic iron (Fe) restriction. In these conditions, chronic immune activation or genetic mutations upregulate the Fe regulating hormone hepcidin, which in turn inhibits activity of ferroportin, the only known Fe exporter. Hepcidin excess thus imposes a severe form of hypoferremia as Fe liberated via hemoglobin recycling in macrophages, nutritional iron absorbed by enterocytes, and other stored Fe cannot be exported to the plasma iron-carrier…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.